HIV i-Base news story
A second study presented at CROI 2026 reported on the studies that led to selecting the 11 mg dose of MK-8527 (the successor compound to islatravir) that will be used in a once-monthly oral formulation in phase 3 PrEP studies.
This was decided based on PK results using doses from 6 mg to 12 mg from five phase 1 studies and one phase 2 study.
Read the full news story here.
View all HIV i-Base reports from CROI 2026
Source : HIV i-Base
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.